Logo Logo
Switch Language to German
Seystahl, Katharina; Stoecklein, Veit; Schüller, Ulrich; Rushing, Elisabeth; Nicolas, Guillaume; Schäfer, Niklaus; Ilhan, Harun; Pangalu, Athina; Weller, Michael; Tonn, Jörg-Christian; Sommerauer, Michael; Albert, Nathalie L. ORCID: 0000-0003-0953-7624 (2016): Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to Ga-68-DOTATATE/-TOC uptake. In: Neuro-Oncology, Vol. 18, No. 11: pp. 1538-1547
Full text not available from 'Open Access LMU'.


Background. The prognosis of patients with progressive meningioma after failure of surgery and radiotherapy is poor. Methods. We retrospectively evaluated the safety and efficacy of somatostatin-receptor (SSTR)-targeted radionuclide therapy (Lu-177-DOTATATE [n = 16], Y-90-DOTATOC [n = 3], or both [n = 1]) in patients with progressive, treatment-refractory meningiomas (5 World Health Organization [WHO] grade I, 7 WHO grade II, 8 WHO grade III) and in part multifocal disease (17 of 20 patients). Results. SSTR radionuclide treatment (median of 3 treatment cycles, median administered dose/cycle 7400 MBq) led to a disease stabilization in 10 of 20 patients for a median time of 17 months. Stratification according to WHO grade showed a median progression-free survival (PFS) of 32.2 months for grade I tumors, 7.2 for grade II, and 2.1 for grade III. PFS at 6 months was 100% for grade I, 57% for grade II, and 0% for grade III. Median overall survival was 17.2 months in WHO grade III patients and not reached for WHO I and II at a median follow-up of 20 months. In the analysis of single meningioma lesions, maximal and mean standardized uptake values in pretherapeutic Ga-68-DOTATOC/-TATE PET/CT were significantly higher in those lesions with radiographic stability after 6 months. In line with this, high expression of SSTR via immunohistochemistry was associated with PFS >6 months. Conclusions. SSTR-targeted radionuclide treatment has activity in a subset of patients with meningioma. Expression of SSTR via immunohistochemistry or radionuclide uptake might serve as a predictive biomarker for outcome to facilitate individualized treatment optimization in patients with uni- and multifocal meningiomas.